Xspray Pharma AB 2024 AR2
The report highlights Xspray Pharma's progress in 2024 as it transitions from an innovative, research-driven company into a commercial drug company. The company focused on building its commercial infrastructure and preparing for the US launch of its lead product candidate, Dasynoc, in 2025. Xspray Pharma also advanced its pipeline, including clinical studies for XS003 nilotinib, and announced a new product candidate, XS025 cabozantinib. Financially, the company secured funding through a preferential rights issue of SEK 135 million and a loan of SEK 100 million to support its upcoming commercialization and expansion efforts.
Company: Xspray Pharma AB
Sector: Health Care
Country: Sweden
Year: 2024
Type: AR2
Pages: 92
Xspray Pharma AB
Annual Report
The report highlights Xspray Pharma's progress in 2024 as it transitions from an innovative, research-driven company into a commercial drug company. The company focused on building its commercial infrastructure and preparing for the US launch of its lead product candidate, Dasynoc, in 2025. Xspray Pharma also advanced its pipeline, including clinical studies for XS003 nilotinib, and announced a new product candidate, XS025 cabozantinib. Financially, the company secured funding through a preferential rights issue of SEK 135 million and a loan of SEK 100 million to support its upcoming commercialization and expansion efforts.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees